SubsidieMeestersMiniaturised Respiratory Assist to treat acute lung failure patients using a breakthrough hyperbaric technology
HBOX Therapies aims to commercialize MiRA, a novel hyperoxygenation therapy for acute lung failure, enhancing patient outcomes while reducing reliance on invasive ventilation.
Projectdetails
Introduction
Acute lung failure (ALF) is the third leading cause of death globally and is characterised by severe respiratory impairment. When non-invasive ventilation (NIV) fails, the treatment escalates to invasive mechanical ventilation (IMV) - the current standard of care for ALF. IMV is highly invasive, with a high risk of complications and an average in-hospital mortality rate of 35%, costing thousands of euros per patient. Hospitals have signalled an unmet need for safe and adequate alternatives to IMV in ALF.
MiRA Therapy
HBOX Therapies GmbH is bringing MiRA (Miniaturised Respiratory Assist) to market: a disruptive and innovative hyperoxygenation therapy that combines unrivalled blood oxygenation and CO2 removal to treat ALF patients while they are awake. Such a breakthrough therapy has the potential to be the first treatment option for ALF patients who fail NIV.
Benefits of MiRA
MiRA therapy has an outstanding cost-effectiveness and improved patient outcomes by avoiding or limiting the need for IMV and further respiratory deterioration in these patients. The growing incidence and prevalence of respiratory diseases causing ALF suggest that there are up to 6 million ALF patients who could benefit from MiRA every year, representing a market potential of €10.4 billion per year.
Technology Overview
Behind MiRA, there is our extracorporeal hyperbaric blood oxygenation (HBOX) technology - 2 patents protect the technology and the approach. HBOX has been validated in animal trials (TRL 5) and we now need to:
- Finalise the integrated system for improved safety and efficacy.
- Complete clinical studies.
- Obtain MDR/CE certification for the MiRA medical device to commence commercialisation.
Future Expectations
We expect the results of the MiRA project to accelerate the market entry of HBOX and to serve as a platform technology for additional clinical applications in the future. The EIC support will be key for our company to establish itself as a leading company in the respiratory industry.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 4.484.410 |
Tijdlijn
| Startdatum | 1-5-2024 |
| Einddatum | 31-8-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- HBOX THERAPIES GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
PArtial REbreathing for Migraine with AuraThe Rehaler is a patented non-drug device for migraine with aura that aims to provide effective relief through CO2 and O2 modulation, supported by a large-scale clinical trial for regulatory approval. | EIC Accelerator | € 1.481.076 | 2023 | Details |
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoringThe Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations. | EIC Accelerator | € 2.299.633 | 2023 | Details |
Saving Cardiac Arrest Patients with Hypothermic Lung Conservative Liquid VentilationOrixha's LuncoLive project aims to clinically validate the Vent2Cool device for rapid cooling of cardiac arrest patients, enhancing survival rates while minimizing costs and environmental impact. | EIC Accelerator | € 2.449.869 | 2023 | Details |
Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)AMT Medical aims to revolutionize coronary artery disease treatment by developing a minimally invasive, cost-effective CABG surgery using innovative ELANA technology, seeking $7.5M for clinical validation and market entry. | EIC Accelerator | € 2.497.469 | 2022 | Details |
Advanced Sterilization Capability with Low Environmental footprint for Patient Infection Optimized SafetyAURORA's ASCLEPIOS project aims to commercialize a novel non-thermal plasma sterilization technology for medical devices, enhancing patient safety and environmental protection while boosting production capacity. | EIC Accelerator | € 2.499.139 | 2023 | Details |
PArtial REbreathing for Migraine with Aura
The Rehaler is a patented non-drug device for migraine with aura that aims to provide effective relief through CO2 and O2 modulation, supported by a large-scale clinical trial for regulatory approval.
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoring
The Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations.
Saving Cardiac Arrest Patients with Hypothermic Lung Conservative Liquid Ventilation
Orixha's LuncoLive project aims to clinically validate the Vent2Cool device for rapid cooling of cardiac arrest patients, enhancing survival rates while minimizing costs and environmental impact.
Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)
AMT Medical aims to revolutionize coronary artery disease treatment by developing a minimally invasive, cost-effective CABG surgery using innovative ELANA technology, seeking $7.5M for clinical validation and market entry.
Advanced Sterilization Capability with Low Environmental footprint for Patient Infection Optimized Safety
AURORA's ASCLEPIOS project aims to commercialize a novel non-thermal plasma sterilization technology for medical devices, enhancing patient safety and environmental protection while boosting production capacity.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Biomimetic Membranes for Organ SupportBioMembrOS aims to develop advanced biomimetic membranes for artificial respiration devices by mimicking the gas exchange structures of fish and birds to enhance efficiency and hemocompatibility. | EIC Pathfinder | € 2.897.578 | 2024 | Details |
FIBAIR - Inhalation spray nozzles with improved air mixing for lung fibrosisHet project ontwikkelt nieuwe mixkamer-technologie voor inhalatoren om de behandeling van longfibrose bij (ex-)COVID-19-patiënten te verbeteren en de levensverwachting te verhogen. | Mkb-innovati... | € 270.891 | 2020 | Details |
Saving the Brain of patient in emergencyHet project onderzoekt de haalbaarheid van een draagbaar koelingsapparaat om hersenletsel bij patiënten in noodsituaties te voorkomen. | Mkb-innovati... | € 20.000 | 2020 | Details |
Low and very-low-field 3D magnetic resonance spirometry for advanced regional exploration of respiratory diseasesV|LF-Spiro3D aims to democratize 3D MR spirometry for lung function assessment using low-cost MRI techniques, enhancing patient safety and comfort while improving respiratory disease diagnostics. | EIC Pathfinder | € 3.584.656 | 2023 | Details |
Rapid Affordable Microbiota Analysis at the point of NeedBforCure's RAMAN project aims to develop a rapid, affordable microbiota analysis device for point-of-need testing, enhancing health and production outcomes in various sectors. | EIC Transition | € 2.466.223 | 2024 | Details |
Biomimetic Membranes for Organ Support
BioMembrOS aims to develop advanced biomimetic membranes for artificial respiration devices by mimicking the gas exchange structures of fish and birds to enhance efficiency and hemocompatibility.
FIBAIR - Inhalation spray nozzles with improved air mixing for lung fibrosis
Het project ontwikkelt nieuwe mixkamer-technologie voor inhalatoren om de behandeling van longfibrose bij (ex-)COVID-19-patiënten te verbeteren en de levensverwachting te verhogen.
Saving the Brain of patient in emergency
Het project onderzoekt de haalbaarheid van een draagbaar koelingsapparaat om hersenletsel bij patiënten in noodsituaties te voorkomen.
Low and very-low-field 3D magnetic resonance spirometry for advanced regional exploration of respiratory diseases
V|LF-Spiro3D aims to democratize 3D MR spirometry for lung function assessment using low-cost MRI techniques, enhancing patient safety and comfort while improving respiratory disease diagnostics.
Rapid Affordable Microbiota Analysis at the point of Need
BforCure's RAMAN project aims to develop a rapid, affordable microbiota analysis device for point-of-need testing, enhancing health and production outcomes in various sectors.